FDA Issues Second Warning Letter Of 2023 Over Potentially Misleading Efficacy Claims Regarding Inhaler - Life Sciences, Biotechnology & Nanotechnology
On August 15, 2023, the U.S. Food and Drug Administration (FDA) published a warning letter to AstraZeneca Pharmaceuticals LP, alleging that a professional sales brochure...
Patrickc Gallagher Kellya Bonner Office Of Prescription Drug Promotion Drug Administration Life Sciences Technologies Industry Group
Source: mondaq.com